Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Antimycin A4: A Precision Tool for Mitochondrial Energy a...

    2026-03-10

    Antimycin A4: A Precision Tool for Mitochondrial Energy and Lipid Metabolism Research

    Principle and Mechanistic Overview

    Antimycin A4 (CAS No.: 27220-59-3) is a chemically defined antibiotic compound derived from Streptomyces species. Its dual mechanism of action—simultaneously functioning as an ATP-citrate lyase inhibitor and a mitochondrial respiratory chain inhibitor—enables precise interrogation of core metabolic pathways. Specifically, Antimycin A4 disrupts electron transport between cytochromes b and c1, directly impeding mitochondrial energy generation and, by inhibiting ATP-citrate lyase (Ki = 64.8 μM against magnesium citrate), blocks the conversion of citrate to acetyl-CoA, a precursor for fatty acid and cholesterol biosynthesis.

    This multifaceted activity positions Antimycin A4 as an indispensable energy metabolism research tool, particularly in experimental models requiring the uncoupling of lipid biosynthesis from mitochondrial ATP production. Its capability to reduce serum triglyceride and LDL-cholesterol levels has also been leveraged in translational models of metabolic disease and cancer metabolism research. Beyond metabolic studies, Antimycin A4 exhibits robust antibacterial activity and is used as a commercial fungicide, broadening its applied utility.

    The foundational work by Barrow et al. (Journal of Antibiotics, 1997) established the antimycin class—including Antimycin A4—as potent inhibitors of ATP-citrate lyase, with well-characterized structural and functional attributes. This reference continues to inform best practices in bench research and protocol optimization.

    Step-by-Step Workflow and Protocol Enhancements

    1. Compound Handling and Preparation

    • Storage: Maintain Antimycin A4 at -20°C in its desiccated form. To ensure maximal activity, avoid repeated freeze-thaw cycles.
    • Solubility: Antimycin A4 is soluble in DMSO. Prepare fresh stock solutions (commonly 10–20 mM) immediately before use; avoid long-term storage of working solutions.
    • Working Concentrations: For most in vitro assays, final concentrations range from 1 to 50 μM, optimizing for cell type and experimental endpoint.

    2. Application in Cellular Assays

    • Metabolic Flux Analysis: Pre-treat cells with Antimycin A4 (e.g., 10 μM) for 30–60 minutes prior to initiating Seahorse XF Analyzer or equivalent mitochondrial function assays. This directly inhibits electron transport at the cytochrome b–c1 complex, producing a quantifiable drop in oxygen consumption rate (OCR).
    • Lipid Biosynthesis Studies: Add Antimycin A4 at 10–20 μM concurrently with radiolabeled acetate or glucose to block ATP-citrate lyase. This leads to a measurable reduction in de novo fatty acid and cholesterol synthesis, as determined via GC/MS or TLC quantification.
    • Cancer Cell Cytotoxicity: Employ Antimycin A4 in cell viability or clonogenic assays to dissect the dependency of cancer cells on mitochondrial respiration and lipid biosynthesis simultaneously. Dose-response curves typically reveal IC50 values in the low micromolar range for sensitive lines.
    • Antibacterial and Fungicide Testing: Use standard broth microdilution or disk diffusion protocols to evaluate activity against bacterial and fungal pathogens, leveraging the compound’s antibiotic properties.

    3. Protocol Enhancements for Reproducibility

    • Use APExBIO-verified Antimycin A4 (SKU C8711) to ensure batch-to-batch consistency and purity, minimizing confounding variables in metabolic assays.
    • Incorporate parallel controls using vehicle-only (DMSO) and, if relevant, known inhibitors of mitochondrial or cytosolic pathways for benchmarking.
    • For high-content imaging or live-cell analyses, optimize exposure times to minimize off-target cytotoxicity while maintaining pathway specificity.

    Advanced Applications and Comparative Advantages

    Dissecting Dual Pathways in Metabolic Research

    Antimycin A4’s dual action as an ATP-citrate lyase inhibitor and mitochondrial respiratory chain inhibitor allows scientists to uniquely discriminate between cytosolic and mitochondrial contributions to energy and lipid metabolism. This precision is especially valuable in:

    • Cancer Metabolism Research: Many tumors shift between glycolytic (Warburg effect) and oxidative metabolic states. Antimycin A4 enables targeted interrogation of both pathways, facilitating the identification of metabolic vulnerabilities for translational therapy development (complemented by this article).
    • Metabolic Disease Modeling: By blocking fatty acid and cholesterol biosynthesis, Antimycin A4 has been used in models of obesity, atherosclerosis, and diabetes to characterize the interplay between mitochondrial dysfunction and dyslipidemia.
    • Benchmarking with Other Inhibitors: In contrast to single-pathway inhibitors, Antimycin A4’s dual inhibition profile provides a reference point for evaluating compound selectivity and off-target effects, as detailed in scenario-driven guidance.

    Integration Into High-throughput and Translational Workflows

    Antimycin A4’s compatibility with automated liquid handling and high-throughput screening platforms supports large-scale drug discovery initiatives. Its defined mechanism and validated performance are referenced in numerous peer-reviewed protocols, including those focusing on cell viability and metabolic flux assays (protocol extension discussed here).

    Quantified Performance Metrics

    • Ki for ATP-citrate lyase: 64.8 μM (against magnesium citrate substrate), as reported in the foundational reference study.
    • IC50 for mitochondrial inhibition: Typically observed at 1–10 μM in mitochondrial respiration assays, with rapid and sustained suppression of OCR.
    • Reproducibility: APExBIO’s Antimycin A4 (SKU C8711) demonstrates <5% variability in metabolic inhibition endpoints across independent batches, outperforming generic alternatives.

    Troubleshooting and Optimization Tips

    • Issue: Variable Inhibition in Cell-based Assays
      Solution: Confirm Antimycin A4 stock solution integrity. Prepare fresh DMSO stocks each session and verify compound solubility before dilution. Ensure even mixing and rapid addition to cell culture to avoid precipitation or uneven dosing.
    • Issue: Off-target Cytotoxicity
      Solution: Titrate Antimycin A4 concentrations to identify minimal effective doses. Include time-course studies to distinguish acute mitochondrial inhibition from secondary cytotoxic effects. Use parallel vehicle controls and orthogonal readouts (e.g., LDH release, caspase activation) for confirmation.
    • Issue: Inconsistent Results Across Cell Types
      Solution: Confirm cell line authentication and passage number. Some lines have altered mitochondrial content or metabolic profiles affecting sensitivity; pilot experiments are recommended.
    • Issue: Loss of Activity Over Time
      Solution: Avoid long-term storage or repeated freeze-thaw of working solutions. Use Antimycin A4 stocks within hours of preparation, and store at -20°C as per APExBIO guidelines.

    For more comprehensive troubleshooting, the article "Resolving Cell Metabolism Assay..." complements these strategies by providing scenario-driven solutions for common lab challenges.

    Future Outlook: Expanding the Impact of Antimycin A4

    As the landscape of metabolic and cancer research evolves, Antimycin A4 is poised to remain a cornerstone tool for interrogating energy and lipid homeostasis. Ongoing advances in high-resolution respirometry, single-cell metabolomics, and translational disease models will further expand the compound’s utility. Future work may focus on:

    • Developing Antimycin A4-based combination protocols for synergistic targeting of metabolic vulnerabilities in cancer and metabolic disorders.
    • Adapting workflows for stem cell research, neurodegenerative models, and immunometabolic studies.
    • Leveraging Antimycin A4 as a benchmark for next-generation mitochondrial and cytosolic pathway inhibitors.

    For researchers seeking robust, reproducible, and validated metabolic insights, Antimycin A4 from APExBIO offers unmatched quality and consistency, supported by peer-reviewed literature and a legacy of foundational discoveries (Barrow et al., 1997).

    Conclusion

    Antimycin A4 stands at the forefront of energy metabolism research, offering dual-pathway inhibition for a new era of experimental precision. Its integration into diverse workflows—from basic mitochondrial studies to advanced cancer metabolism research—underscores its versatility and reliability. By following best-practice protocols and leveraging APExBIO’s commitment to quality, researchers can generate high-impact, reproducible data that drive discovery and translational innovation.